Dublin, Aug. 28, 2020 (GLOBE NEWSWIRE) -- The "Coronavirus Disease 2019 (COVID-19) Impact on Immunology Trials - July 2020" report has been added to ResearchAndMarkets.com's offering.

Since the beginning of March 2020, clinical trial operations were most disrupted as a result of the COVID-19 pandemic. This report summarizes the impact on immunology patient, clinical trial logistics, and key opinion leader (KOL) insights on the long-term impact of the pandemic.

Report Scope

  • Global overview of changes to clinical practice and clinical trial logistics in H1 2020 in 8MM (US, EU5, Japan, Canada)
  • Summary of primary research with Immunology Key Opinion Leaders
  • Forward-looking perspective of potential long-term ramifications of COVID pandemic

Reasons to Buy

  • Understand the impact of COVID-19 on immunology clinical trials
  • Obtain a snapshot of the regulatory guidance issued by the US FDA, EMA, and Health Canada
  • Understand the impact of COVID on continuity of care for immunology patients
  • Understand the impact of COVID on clinical trial logistics (including trial recruitment, trial conduct, and supply chain)
  • Understand the potential long-term impact of COVID on clinical trial conduct and clinical practice

Key Topics Covered

1 Immunology Trials Disrupted
1.1 Overview of Immunology Trials Disrupted
1.2 Regulatory Guidance Across the 8MM

2 KOL Insights: Continuity of Care

3 KOL Insights: Trial Logistics
3.1 Recruitment
3.2 Conduct in Isolation
3.3 Supply Chain

4 KOL Insights: Trials Looking Forward
4.1 Clinical Trials Disrupted Due to COVID
4.2 Immunology Clinical Trials Resumed

5 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/5kx76f

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900